Glaukos’ new intraocular implant iDose is on track to complete US Food and Drug Administration trials in 2022, as the company seeks to address glaucoma treatment adherence.
The glaucoma device manufacturer believes its latest drug delivery system could offer an alternative to traditional topical drop medications. The device consists of a titanium intraocular implant filled with a proprietary, concentrated Travoprost formulation. A scleral anchor is designed to hold the device in place.
With a miniature profile – 1.8mm by 0.5mm – the iDose is inserted through a clear corneal incision, enabling direct implantation into the anterior chamber, where it begins the process of sustained drug elution.